Products for Research Use Only

Avitinib

CAT: 0013-GTR19171541-01Size: 2 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0013-GTR19171541-01Size:2 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Avitinib (AC0010) is an orally bioavailable, irreversible inhibitor that selectively targets mutant epidermal growth factor receptor (EGFR), including the T790M resistance mutation. It is used in oncology research to study tumor growth inhibition in EGFR-mutated models, with applications in both in vitro cellular assays and in vivo xenograft experiments.
CAS Number
1557267-42-1
Product Name Alternative
AC 0010, AC0010, AC-0010, Abivertinib, Avitinib, Btk, BTK, Bruton tyrosine kinase, Epidermal growth factor receptor, ErbB-1, EGFR, Inhibitor, HER1, inhibit, JAK3
Field of Research
Cardiovascular Research, Cell Biology, Epigenetics & Chromatin, Signal Transduction, Stem Cell & Developmental Biology
Purity
99.81% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:3.3 mg/mL (6.77 mM) ; DMSO:88 mg/mL (180.5 mM)
Smiles
CN1CCN (CC1) c1ccc (Nc2nc (Oc3cccc (NC (=O) C=C) c3) c3cc[nH]c3n2) cc1F
Molecular Formula
C26H26FN7O2
Molecular Weight
487.53
Storage Conditions
-20°C
Notes
For research use only.

Chemical Information

Abivertinib

Abivertinib is a tyrosine kinase inhibitor targeted against mutant forms of both human epidermal growth factor receptor (EGFR) and Bruton's tyrosine kinase (BTK). It has been investigated for use in the treatment of non-small cell lung cancer (NSCLC) and B-cell malignancies. In binding to and inhibiting EGFR and BTK receptors, abivertinib exerts immunomodulatory effects by preventing the production and release of pro-inflammatory cytokines (e.g. TNF-alpha, interleukins). Abivertinib's potential to depress cytokine production has led to its investigation in the treatment of hospitalized patients with moderate-to-severe COVID-19. The cytokine storm associated with COVID-19 is thought to contribute to disease progression and is associated with poor outcomes in patients - as abivertinib inhibits the release of multiple cytokines at once, it may provide more pronounced clinical benefits as compared to agents targeting single pathways (e.g. interleukin-6 inhibitors). The study is expected to be completed in March 2021.

CAS Number1557267-42-1
PubChem CID72734520
IUPAC NameN-[3-[[2-[3-fluoro-4-(4-methylpiperazin-1-yl)anilino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide
Molecular FormulaC26H26FN7O2
Molecular Weight487.5
XLogP4.2
Topological Polar Surface Area98.4
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count8
Rotatable Bond Count7
Heavy Atom Count36
Formal Charge0
Complexity752
SMILES
CN1CCN(CC1)C2=C(C=C(C=C2)NC3=NC4=C(C=CN4)C(=N3)OC5=CC=CC(=C5)NC(=O)C=C)F
InChI
InChI=1S/C26H26FN7O2/c1-3-23(35)29-17-5-4-6-19(15-17)36-25-20-9-10-28-24(20)31-26(32-25)30-18-7-8-22(21(27)16-18)34-13-11-33(2)12-14-34/h3-10,15-16H,1,11-14H2,2H3,(H,29,35)(H2,28,30,31,32)
InChIKey
UOFYSRZSLXWIQB-UHFFFAOYSA-N
Chemical Structure
2D Structure
2D structure of Abivertinib
CAS: 1557267-42-1
CID: 72734520
Formula: C26H26FN7O2
MW: 487.5
Interactive 3D Structure
Loading 3D structure...
Computed Properties
PropertyValue
Molecular Weight487.5
XLogP34.2
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count8
Rotatable Bond Count7
Exact Mass487.21320126
Monoisotopic Mass487.21320126
Topological Polar Surface Area98.4 Ų
Heavy Atom Count36
Formal Charge0
Complexity752
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count1
Compound Is CanonicalizedYes